£1.3M
The Fife-based retinal imaging company secured £1.3m from Greenwood Way Capital and Scottish Enterprise.
GW
Greenwood Way Capital
Venture CapitalGreenwood Way Capital introduces early stage companies with disruptive technologies to suitable investors.
Portfolio
6
companies
By category
- MedTech£4.7M
- FinTech£4.5M
- BioTech£3.7M
- CleanTech£2.8M
- HealthTech£2.0M
By location
- London£4.5M
- Cambridge£3.7M
- United Kingdom£2.8M
- Fife£2.8M
- Glasgow£2.0M
- Other£1.9M
Portfolio companies
Epipole
Epipole develops handheld retinal imaging devices for clinical use.
L
Landytech
Landytech builds software for investment reporting and risk analytics.
Micrima
Micrima develops radio-wave breast imaging technology for clinical use.
NT
Novel Technologies Holdings
Novel Technologies Holdings develops permanent silver-based antimicrobial treatments for textiles and surfaces.
PR
Power Roll
Power Roll creates ultra-low-cost flexible film for solar energy generation and storage.
SF
Sphere Fluidics
Sphere Fluidics develops single cell analysis and characterisation systems for biopharmaceutical discovery.
Team
IL
Ian Leigh
Founder
Recent investments
$6.0M
Adelie Capital and Greenwood Way Capital backed the round, which will fund team expansion.
"This is a major achievement in the development of our company. Our Investors share our commitment to empower asset owners, managers, and advisors by delivering a more enriched experience for managing their investments and making decisions on one single version of the truth. This investment will support our aggressive growth plans to become the vendor of choice for investment reporting and analytics in our target markets."
£1.9M
The funding round was led by Technology Venture Partners alongside government backing to support the commercialisation of a new breast scanning system.
"this investment will allow us to move the company into the next phase with a system that has a place in a clinical workflow and more exciting functionality to come as soon as clinical data collection can re commence"
£2.8M
Green Angel Syndicate and other investors backed the £2.8m raise, which includes UK Government Future Fund support.
"The success of our funding round and the quality of our investors reflects the global commercial potential for our technology,"
£1.5M
The funding will prepare the company for its introduction into the United States ophthalmic imaging market.
"We’ve worked with ophthalmologists to test and refine features and capabilities, and will use this funding to implement the key changes needed,"